The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents

Sebastian Siller1,2*, Michael Lauseker3, Philipp Karschnia1,2, Maximilian Niyazi2,4, Sabina Eigenbrod5, Armin Giese5 and Joerg-Christian Tonn1,2

Abstract

MGMT-promoter methylation is associated with favorable outcome in glioblastoma. The aim of this study was to determine whether the absolute number of methylated Cytosine-Guanine-dinucleotide-(CpG-)sites within the DMR-2 island of the MGMT-promoter may correlate with outcome in a qualitative or quantitative fashion. In a cohort of newly diagnosed glioblastoma patients treated with stereotactic biopsy or open tumor resection plus concomitant chemoradiotherapy, we assessed MGMT-promoter methylation by methylation-specific polymerase-chain-reaction (MSP). Methylation of the CpG-sites 74–98 within the MGMT-promoter region was additionally analysed by Sanger sequencing, and the total number of methylated CpG-sites was correlated with outcome using proportional hazards models. 215 patients with glioblastoma were identified and stratified per MSP (positive: 53%, negative: 47%). Among MSP-positive tumors, hierarchical clustering identified three subgroups with different methylation rates (median: 80% vs. 52% vs. 47%), indicating a site-dependent methylation propagation. The methylation status of a given CpG-site indicated a neighborhood-dependent methylation propagation. Survival was linearly associated with the cumulative number of methylated CpG-sites. This was particularly true in patients who received at least one adjuvant cycle of temozolomide. Notably, all CpG-sites analyzed contributed similarly to effect size; this enabled a further predictive substratification of MSP-positive tumors with median OS ranging from as low as 17.1 months (< 18 methylated CpG-sites) to as high as 26.2 months (≥ 18 methylated CpG-sites) in the overall cohort. All in all, total number of methylated CpG-sites may correlate with outcome in a linear fashion. Such analysis may therefore add further predictive value to conventional methods of determining the MGMT-promoter status.

Keywords: Glioblastoma, MGMT promoter, Methylation status, Temozolomide, Linear correlation, Methylation-specific polymerase-chain-reaction, MSP, Sanger sequencing

Introduction

Glioblastoma is the most frequent primary brain tumor with a devastating natural history [23]. Surgical treatment followed by combined chemoradiotherapy and maintenance chemotherapy represents the ‘standard of care’ in such tumors [32]. Epigenetic silencing of O-6-methylguanine-DNA methyltransferase (MGMT) by promoter methylation has been shown to be strongly associated with response to chemotherapy with alkylating agents [12, 27]. Hence, numerous clinical trials have stratified patients according to MGMT promoter methylation status [12, 14, 27].
Although MGMT promoter status has been shown to be of relevance with respect to treatment and outcome in glioblastoma patients, a consensus on methods and cutoff values to determine MGMT promoter methylation remains to be defined. Methylation-specific polymerase chain reaction analysis (MSP) [7, 12, 27] and pyrosequencing are among the most frequently used methods [5, 11, 21, 22]. Such methods usually analyze only a small number of the Cytosine-Guanine dinucleotide (CpG) sites within the differentially methylated region-2 (DMR-2) island of the MGMT promoter region, and results are typically reported either as ‘methylated’ or ‘unmethylated’ by laboratory core facilities [2, 19]. However, such approaches may miss the potential role of the patient’s individual CpG methylation pattern, the effect of quantitative differences in methylation, and cases of “grey zone methylation” as recently proposed [13, 24]. It is therefore unclear whether there might be a correlation between outcome and number of methylated CpG sites, particularly also those sites which are not analyzed by standard techniques like MSP.

In the present study, we describe a large cohort of patients with histologically verified glioblastoma treated at a single academic neuro-oncology center with standard of care including alkylating chemotherapy, where both MSP and Sanger sequencing (Sseq) were applied in parallel for MGMT promoter methylation testing and evaluated independently. Since, Sseq enables analysis of the individual methylation status of 25 single CpG sites (including those 9 CpG sites covered by MSP) located in the DMR-2 island and downstream of that [2], we aimed to elucidate the above mentioned role of the individual CpG site methylation profile on outcome and help to improve prognostic/predictive stratification of glioblastoma patients for personalized treatment concepts as compared to current standard approaches.

**Material and methods**

**Patients**

The institutional database of the Center for Neuro-Oncology at the University Hospital of the LMU Munich was searched for all adult patients with a de-novo histopathological diagnosis of a supratentorial glioblastoma consecutively treated with radiotherapy (RT) plus temozolomide (TMZ) between April 2005 and June 2015. The study was reviewed and approved by the local Institutional Review Board (IRB) of the Ludwig-Maximilian-University Munich (approval number 703/16), and a waiver of consent was issued by the IRB.

**Treatment**

Patients underwent either open tumor resection (OTR) or stereotactic biopsy according to the recommendations of our interdisciplinary tumor board. The extent of OTR was determined by postoperative magnetic resonance imaging (MRI) provided within 72 h after surgery, and scored according to the study of Stummer et al. [26] either as gross-total tumor resection (GTR, no residual contrast enhancement in post-contrast T1-weighted sequences) or subtotal tumor resection (STR, any contrast enhancement with a volume of more than one voxel in the post-contrast T1-weighted images). Patients were scheduled to receive combined chemoradiotherapy (RT/TMZ) within 3 weeks upon histopathological diagnosis per ‘standard of care’ in accordance to the EORTC 22981/26981 protocol [28], and adjuvant TMZ up to 6 cycles was initiated within 6 weeks after chemoradiotherapy as consolidation per European guidelines whenever possible [30]. None of our patients > 70 years was treated with hypofractionated radiotherapy as this therapeutic approach was incorporated in our institutional practice after the recruitment period for this study [20]. Patients who refused or had contraindications for combined chemoradiotherapy received TMZ alone.

**Follow-up imaging**

Gadolinium contrast-enhanced MRI was performed six weeks after completion of RT/TMZ and in 3 months-intervals thereafter or in any case of clinical deterioration. Treatment response as well as disease progression was assessed by our interdisciplinary tumor board according to the RANO criteria [31]. In case of diagnostic uncertainties, O-(2-[18F]fluoroethyl)-1-tyrosine (18F-FET) positron emission tomography (PET) with or without subsequent stereotactic biopsy was provided.

**Integrative diagnosis**

Tissue specimens of all patients were reviewed according to the 2016 WHO classification of central nervous system tumors [17]. Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations were examined using pyrosequencing as previously described [6].

**Isolation of nucleic acids**

DNA was isolated from each tumor specimen using the QIAamp® DNA Micro Kit (Qiagen, Hilden, Germany). DNA isolation from normal blood lymphocytes was performed either using magnet-based techniques (QuickPickTM gDNA, Bionobile, Turku, Finland) or the QIAmp DNA Blood Kit (Qiagen, Hilden, Germany). The quantity and purity of DNA were assessed using the NanoDrop® ND-1000 Spectrophotometer (NanoDrop, Wilmington, NC). DNA recovery from each stereotactic biopsy sample amounted to around 30–60 μg/l.
Bisulfite modification of DNA
The bisulfite conversion reaction was performed with a total of 200–400 ng DNA by use of the EpiTect® Bisulfite Kit (Qiagen, Hilden, Germany). In this reaction, all cytosines except for their methylated counterparts are converted to uracil. For the detection of promoter hypermethylation of the MGMT gene, both MSP and Sanger sequence analysis were performed using bisulfite-modified DNA.

MGMT promoter methylation: methylation-specific PCR
For MSP, two pairs of primers encompassing CpG sites 76–80 and 84–87 (Fig. 1a) specific for either the methylated or the unmethylated MGMT promoter region were used as previously described [8]. Tumors were graded as 'strongly methylated' (ratio of C/T-peak > 1.00) or 'partially methylated' (ratio of C/T-peak 0.50–1.00), while unmethylated CpG sites were subdivided in 'weakly methylated' (ratio of C/T-peak 0.10–0.49) and 'non-methylated' (ratio of C/T-peak < 0.10) as described by Grasbon-Frodl et al. [10].

MGMT promoter methylation: Sanger sequence analysis of bisulfite-modified DNA
Sequencing and data analysis was performed as previously described [6, 10]. In brief, a 316 base pairs (bp) PCR product encompassing 25 CpG sites of the MGMT promoter (CpG sites 74–98; Fig. 1a) was obtained using the primers described by Moellemann et al. [22]. The respective CpG sites were classified as 'methylated' if they were 'strongly methylated' (ratio of cytosine/thymine [C/T]-peak > 1.00) or 'partially methylated' (ratio of C/T-peak 0.50–1.00), while unmethylated CpG sites comprised 'weakly methylated' (ratio of C/T-peak 0.10–0.49) and 'non-methylated' (ratio of C/T-peak < 0.10) CpG sites. Using these cutoff values has been shown to provide an easy classification with very high inter-rater reliability [6]. The total number of methylated CpG sites was calculated for each patient.

Raters were blinded for the clinical outcome data. MSP and Sseq were applied in parallel and evaluated independently.

Statistical analysis
All statistical analyses were performed for complete datasets with R 3.4 (Comprehensive R Archive Network, CRAN) by an experienced biostatistician (ML) in cooperation with the neuro-oncological team (SS, JCT). The reference point of this study was the date of surgery. Endpoints were progression-free survival (PFS), post-recurrence survival (PRS) and overall survival (OS). Patients were followed until death from any cause, or censored at day of last follow-up. Database closure was December 2018. Survival data were analyzed with the Kaplan–Meier method. For comparative analyses the log-rank test was used. Prognostic factors were obtained from proportional hazards models (Cox regression models). Multiple proportional hazards models for all CpG sites were fit by component wise likelihood based boosting [3]. Martingale residuals were plotted to assess the coherence between the total number of methylated CpG sites and survival hazards [29]. Hierarchical clustering of CpG sites was done using the Jaccard distance and the maximum linkage criterion [16]. The Bonferroni–Holm correction was used in case of multiple testing [15]. Correlation analysis was performed using the Spearman and Pearson correlation coefficient testing. p values below 0.05 were considered statistically significant.

Results
A total of 215 consecutively treated patients with IDH1/2 wild-type tumors were encountered. Patients’ baseline characteristics are summarized in Table 1. OTR and biopsy were done in 100 (46.5%) and 115 (53.5%) patients, respectively; there was no significant difference in the proportion of patients with OTR versus biopsy between the subgroups of patients harboring MSP-positive or -negative tumors. RT/TMZ was provided in all patients afterwards. Biopsied patients were significantly older (63 vs. 58 years, p < 0.01), had worse clinical pretreatment status (median Karnofsky Performance Status [KPS]: 80 vs. 90, p < 0.01), and more often deep seated or multifocal tumor location (49.6% vs. 19.0%, p < 0.01).
According to MSP, 113 tumors (52.6%) were graded as MSP-positive and ‘methylated’. MGMT promoter methylation maps of the study population as determined by Sseq are given in Fig. 1b. Methylation patterns were heterogeneous between the individual patients, and CpG sites at the boundaries of the analyzed promoter island were found to be less often methylated. Patients with MSP-positive (− negative) tumors exhibited a wide range of cumulative numbers for methylated CpG sites [8–24 (median: 18) vs. 0–13 (median: 1)]. Generally, patients with MSP-positive (− negative) tumors showed higher (lower) cumulative numbers of methylated CpG sites (median: 18 vs. median: 1). Moreover, the cumulative number of methylated CpG sites within the MSP-primer region (CpG sites 76–80 and 84–87) were positively inter-correlated with the cumulative number of methylated CpG-sites outside the MSP-primer region (CpG sites 74, 75, 81–83 and 88–98) (Pearson correlation coefficient: 0.876; p < 0.001).

Among MSP-positive tumors, hierarchical clustering identified three subgroups with different methylation rates (Fig. 1c). Methylation level was highest in CpG sites 79–> 94 plus CpG site 98 (cluster I; median methylation rate: 80%), intermediate in CpG sites 74–> 78 (cluster II; median methylation rate: 52%), and lowest in CpG sites 95–> 97 (cluster III; median methylation rate: 47%). The differences in methylation levels between each of the clusters were statistically significant (p < 0.01). Methylated CpG sites were inter-correlated among themselves: CpG sites were more likely to be methylated when the bordering CpG site was also methylated (i.e. neighborhood-dependent methylation propagation) (Fig. 1d).

**Table 1 Clinical characteristics**

| Characteristic          | Value                          |
|-------------------------|--------------------------------|
| Gender                  | Male/female, (n/n, %/%)        |
| Age (years)             | Median (range)                 |
| KPS                     | Median (range)                 |
| Tumor side              | Left/right (n/n, %/%)          |
| Tumor location          | Lobar/deep*/*multifocal (n/n/n, %/%/%) |
| Surgical treatment      | GTR (n, %)                     |
|                         | STR (n, %)                     |
|                         | Biopsy (n, %)                  |

* Deep seated = not lobarly located (e.g. thalamus or basal ganglia)

Outcome and markers of outcome in the overall cohort

At the time of last follow up, 211 patients experienced progressive disease and 199 patients were deceased. Death was tumor-related in all patients. Median PFS and OS were 7.9 and 14.9 months, respectively. Median survival for MSP-positive (MSP-negative) tumors was 21.4 (12.1) months (p < 0.001; Fig. 2a). Progression free survival was also highly divergent (Fig. 2b).

Uni- and multivariable prognostic modelling are summarized in Table 2. On univariate analysis, the cumulative number of methylated CpG sites, MSP-positivity, younger age, and OTR were associated with increased PFS and OS. Additionally, a pre-treatment KPS ≥ 80 and a lobar tumor location were prognostic for favourable outcome. On multivariable models, the cumulative number of methylated CpG sites, younger age, and OTR retained their relevance as positive outcome markers on PFS/OS. Of note, the significance of the MSP status was lost in multivariable analysis. The adjusted hazard ratios for each methylated CpG site for disease progression and death were 0.94 (95% CI 0.93–0.96) and 0.94 (95% CI 0.92–0.96), respectively. The respective adjusted fitted survival curves are displayed in Fig. 3a with median OS ranging from as low as 10 months (0 methylated CpG sites) to as high as 28 months (25 methylated CpG sites).

Survival for those MSP-positive tumors exhibiting < or ≥ 18 methylated CpG sites (the cut-point for
stratification represents the median of the distribution among MSP-positive tumors) was also highly divergent ($p = 0.002$; Fig. 3b); the survival curve of MSP-positive tumors lied in between that of tumors with $<18$ (median OS: 17.1 months; 54 patients) or $\geq 18$ (median OS: 26.2 months; 59 patients) methylated CpG sites. Baseline patients’ characteristics did not significantly differ between the subgroups of MSP-positive tumors with $<or> = 18$ methylated CpG sites. Stratification of MSP-negative tumors was not possible analogously since the overall median number of methylation CpG sites was too low in this group. All clusters (as displayed in Fig. 1c) were involved to a various degree in either of the prognostic subgroups; none of the clusters per se was associated with a favourable outcome (data not shown).

We plotted martingale residuals (Y-axis) versus the accumulated number of methylated CpG sites (X-axis; see Additional file 1: Fig. S1) to analyze whether the effect of the number of methylated CpG sites on the hazard ratio is linear and found the local linear regression (locally weighted scatterplot smoothing, LOWESS) curve to be linear in decrease pointing towards a linear effect. All of the analyzed CpG sites were significantly correlated with outcome; we did not find CpG sites or CpG subgroups with superior predictive impact within the investigated window of this series. Plotting martingale residuals versus the accumulated number of methylated CpG sites also revealed the same linear effect when respective CpG sites were classified as methylated in (1) case of a ratio of cytosine/thymine peak $>0.10$ (orange, green and yellow labeling in Fig. 1b) or (2) case of a ratio of cytosine/thymine peak $>1.00$ (green labeling in Fig. 1b) as displayed in Additional file 3: Fig. S3; however, clearest effects were seen when respective CpG sites were classified as methylated in case of a ratio of cytosine/thymine peak $>0.50$ (green and yellow labeling in Fig. 1b).

Calculating the local linear regression (LOWESS) curves also revealed a linear effect of the number of methylated CpG sites on the hazard ratio for survival in both the subgroup of patients undergoing biopsy ($n = 115$) and that undergoing resection ($n = 100$) (see

| Table 2 Prognostic factors |
|-----------------------------|
| **Univariable**             |
| CpG sites                   |
| Per methylated site in Sseq | $0.95 (<0.01/0.93–0.97)$ |
| Age (years)                 |
| Per year                    | $1.02 (<0.01/1.00–1.03)$ |
| KPS                         |
| $<80$ versus $\geq 80$      | $2.00 (<0.01/1.36–2.94)$ |
| Tumor side                  | $1.25$ (n.s./0.95–1.64)  |
| Left versus right           | $1.16$ (n.s./0.87–1.53)  |
| Tumor location              | $0.90$ (n.s./0.68–1.20)  |
| Lobar versus other          | $0.82$ (n.s./0.61–1.1)   |
| MSP status                  | $0.44$ (<0.01/0.33–0.60) |
| Positive versus negative    | $0.45$ (<0.01/0.34–0.61) |
| Surgical treatment          | $0.64$ (<0.01/0.48–0.86) |
| OTR versus biopsy           | $0.59$ (<0.01/0.45–0.80) |
| **Multivariable**           |
| CpG sites                   |
| Per methylated site in Sseq | $0.96$ (<0.01/0.93–0.99) |
| Age (years)                 | $1.02$ (<0.01/1.01–1.04) |
| KPS                         | $1.94$ (n.s./1.30–2.91)  |
| $<80$ versus $\geq 80$      | $2.88$ (<0.01/1.90–4.36) |
| Tumor location              | $1.04$ (n.s./0.74–1.45)  |
| Lobar versus other          | $1.08$ (n.s./0.76–1.53)  |
| MSP status                  | $0.77$ (n.s./0.44–1.34)  |
| Positive versus negative    | $0.68$ (n.s./0.37–1.26)  |
| Surgical treatment          | $0.75$ (n.s./0.54–1.03)  |
| OTR versus biopsy           | $0.63$ (<0.01/0.44–0.89) |
Additional file 2: Fig. S2); adjusted OS for those MSP-positive tumors exhibiting < or > = 18 methylated CpG sites was divergent (resection: \( p = 0.02 \); biopsy: 0.04) and flanked the survival curve of MSP-positive tumors in both subgroups (see Additional file 4: Fig. S4).

When analyzing the subgroup of patients with OS > 3 months that received at least one adjuvant TMZ cycle after RT/TMZ (\( n = 170 \)) in a landmark analysis, we found similar results as compared to the overall cohort: plotting martingale residuals versus the accumulated number of methylated CpG sites resulted in a LOWESS curve that was considered approximately linear in decrease (i.e. linear effect; see Fig. 4); survival for those MSP-positive tumors exhibiting < or > = 18 methylated CpG sites was also highly divergent (\( p < 0.01 \)) and flanked the survival curve of MSP-positive tumors (data not shown). For those patients with OS > 3 months that did not receive any adjuvant TMZ after RT/TMZ due to precedent progressive disease (\( n = 33 \)), no correlation of the accumulated number of methylated CpG sites with survival could be seen.

**Post-recurrence survival**

Median KPS at timepoint of progression was 70. For treatment of progression, 42 patients were primarily re-exposed to TMZ. 10 patients primarily underwent re-radiation, 18 patients re-OTR, 4 patients re-OTR combined with following re-radiation, 18 patients received stereotactic interstitial brachytherapy, 11 patients 5-aminolevulinic acid photodynamic therapy, and 5 patients bevacizumab; 42 of these 66 patients were re-exposed to TMZ afterwards, while 2 patients received bevacizumab and 22 patients best supportive care afterwards. 107 patients received best supportive care solely at the timepoint of progression.

Median overall PRS was 5.5 months, while median PRS for MSP-positive (MSP-negative) tumors was 6.6 (4.8) months (\( p = 0.002 \)). When plotting martingale residuals versus the accumulated number of methylated CpG sites, we found the LOWESS curve to be linear only in the 88 patients with re-exposure to TMZ for post-progression treatment; in the remaining patients, we could not detect a similar linear effect of the number of methylated CpG sites on the hazard ratio for PRS (see Additional file 4: Fig. S4).

**Discussion**

Clinical MGMT promoter status testing often relies on a very limited number of CpG sites within the MGMT promoter region and is reported categorically either as ‘methylated’ or ‘unmethylated’ [2, 19]. Such approaches, however, may miss the potential role of the patient’s individual CpG methylation pattern, quantitative differences in methylation, and cases of “grey zone methylation” as recently proposed [13, 24]. Based on a large uniform cohort of 215 glioblastoma patients, we applied MSP and Sseq testing in parallel and evaluated the results independently. Since Sseq enables analysis of the individual CpG methylation pattern, quantitative differences in methylation, and cases of “grey zone methylation” as recently proposed [13, 24].

Based on a large uniform cohort of 215 glioblastoma patients, we applied MSP and Sseq testing in parallel and evaluated the results independently. Since Sseq enables analysis of the individual CpG methylation pattern, quantitative differences in methylation, and cases of “grey zone methylation” as recently proposed [13, 24].

We found that the cumulative number of methylated CpG sites within the MGMT promoter region is correlated with outcome. In dependence of the number of methylated CpG sites, adjusted OS and PFS were predicted to increase in a stepwise fashion. These findings might explain survival advantages among so-called ‘unmethylated’ but also ‘methylated’ glioblastomas after TMZ (as determined per MSP). When looking on the martingale residuals of the model, a linear positive association between the number of methylated CpG sites
and increased survival (OS or PFS) was demonstrated in the overall cohort. Subgroup analyses revealed that this linear association was present whenever glioblastoma patients were exposed to at least one adjuvant TMZ cycle in both primary situations after initial combined chemoradiotherapy (with regard to OS and PFS) as well as recurrent situations (with regard to PRS)—regardless of the initial surgical procedure for histological assessment (OTR vs. biopsy). No comparable association was seen in those patients without adjuvant resp. recurrent TMZ exposition.

To provide an easy to use tool for clinical practice, we additionally present a two-scaled survival model for MSP-positive tumors in the overall cohort using the median number of methylated CpG sites as cutoff value (0.50) for a larger number of methylated CpG sites which allowed for predictive substratification of patients that are commonly summarized to be ‘methylated’ in terms of standard MSP-testing. Substratification might be particularly relevant when it comes to patients’ guidance by estimating prognosis or treatment decisions beyond standard treatment regimens. For instance, upfront TMZ compared to resection plus conventional chemoradiotherapy among the elderly subpopulation might be a more promising approach for MSP-positive tumors exhibiting a larger number of methylated CpGs. Whether this holds true in prospective cohorts remains to be shown, and no definitive treatment recommendations can be made based upon our retrospective study. However, such a hypothesis will need to be considered in future studies.

Recent studies have focused on substratification of glioblastoma patients by determining appropriate cutoffs and safety margins to distinguish “grey zone” methylation from truly “unmethylated” and truly “methylated” glioblastomas using quantitative MSP and/or pyrosequencing assay analyses. It was demonstrated that the extent of methylation impacts prognosis and enables a three scaled predictive model including a small tumor subgroup exhibiting “grey zone” methylation with a slightly significantly better prognosis than truly “unmethylated” glioblastomas [13, 24]. However, such studies might be of limited explanatory power since individual CpG methylation patterns were not addressed and stratificational differences in the “truly/highly methylated” group were not analyzed, whereas we did find such differences. Of note, in quantitative MSP and pyrosequencing assay analyses, the level of methylation measured is directly influenced by the tumor cell content of the tissue as only an average value is provided, whereas counting the number of CpG sites with a methylation level above a suitable threshold value (e.g., C/T-peak ratio ≥ 0.50) for a larger number of CpG sites, as described here, provides a quantitative readout which is robust to the admixture of some non-tumor cells. Particularly in the era of precision medicine, an increasing body of data supports the demand for more refined techniques for MGMT promoter methylation testing, allowing for a more precise substratification than a two- or three-scaled predictive model, and the Sseq approach, as described in this study, might be a viable option.

Of note, it remains to be shown whether our findings on the correlation between outcome and number of methylated CpG sites will hold true when tumors are graded according to potential future classification systems. In the present study, glioblastoma WHO grade IV was defined by histopathological findings based on the WHO 2016 classification. However, future studies may need to rest their definition of WHO grade on molecular findings. According to the most recent cIMPACT-NOW update, diffuse astrocytomas without IDH mutation formerly assigned to WHO grade II or III might be denoted as WHO grade IV in the presence of specific genetic alternations [18].

In this study, hierarchical clustering identified three distinct clusters of CpG sites with significantly different methylation rates suggesting a site-dependent methylation propagation. Moreover, the correlative matrix of hierarchical clustering uncovered a neighborhood-dependent methylation propagation, i.e. the methylation status of a given CpG site usually matched that of their neighbored CpG sites to some degree. Accordingly, the methylation status of the CpG sites was shown to be inter-correlated within the three distinct clusters and to a lesser degree also throughout different clusters. These correlative distributions, however, overlapped and did not allow accurate extrapolation of methylation levels from one subgroup to another one; therefore analysis of the individual MGMT promoter methylation status cannot be restricted to a single cluster. CpG site- and CpG neighborhood-dependent methylation propagation might have contributed to the observed methylation heterogeneity among MSP-positive tumors. Recently published Bayesian inference modelling of DNA methylation propagation at the MGMT promoter supports the concept of CpG site- and CpG neighborhood-dependent heterogeneous methylation propagation [4].

We did not find CpG hot-spots or subgroups with superior predictive impact within the investigated window of this series. All 25 CpG sites analyzed by Sseq were significantly correlated with outcome. Our findings strongly point to an inter-correlated predictive network of methylated CpG-sites varying among tumors. Studies speculating on the superior predictive impact of a single CpG site on the basis of more or less transcriptional silencing may have not controlled for the effects of inter-correlations in the CpG network of the promoter and
other factors influencing MGMT silencing such as histone demethylation or transcript elongation by alternative polyadenylation and miRNA targeting [1, 9, 19, 25]. Future studies in prospective cohorts are warranted to determine whether there might be an association of individual CpG sites and outcome, however, our study seems not be in support of such a hypothesis.

Conclusions
Collectively, extent of MGMT promoter methylation as determined by number of methylated CpG sites appears to correlate with outcome in a linear fashion. Seeq seems to be feasible in daily clinical practice to extensively analyse a large number of CpG sites within the DMR-2 island. Of note, this method provides a fast turn-round time of only 2–3 days, the amount of tissue/DNA required is small [compared e.g. to next-generation-sequencing (NGS)], standardized analysis provides high inter-rater reliability, and the technological infrastructure required is available at low costs worldwide. An up-front analysis of the individual GpC site methylation status might therefore help to improve the prognostic and predictive stratification of glioblastoma patients, which can be used for more precise prognostic and therapeutic concepts than conventional testing.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40478-021-01134-5.

Additional file 1: Supplementary Fig. S1. Effect of the number of methylated CpG sites on the hazard of mortality: For 215 glioblastoma patients, the patients’ methylated CpG sites were plotted against the patients’ martingale residuals of the model without the variable “methylated CpG sites.” The red line shows the corresponding LOWESS (locally weighted scatterplot smoothing) curve and gives a hint that the true effect of the number of ‘methylated’ CpG sites on the hazard of mortality seems to be linear.

Additional file 2: Supplementary Fig. S2. Effect of the number of methylated CpG sites on the hazard of mortality: the patients’ methylated CpG sites were plotted against the patients’ martingale residuals of the model without the variable “methylated CpG sites.” The red line shows the corresponding LOWESS (locally weighted scatterplot smoothing) curve and gives a hint that the true effect of the number of ‘methylated’ CpG sites on the hazard of mortality seems to be linear.

Additional file 3: Supplementary Fig. S3. Effect of the number of methylated CpG sites on the hazard of mortality in 215 glioblastoma patients: the patients’ methylated CpG sites were plotted against the patients’ martingale residuals of the model without the variable “methylated CpG sites.” The red line shows the corresponding LOWESS (locally weighted scatterplot smoothing) curve and gives a hint that the true effect of the number of ‘methylated’ CpG sites on the hazard of mortality in case of respective CpG sites were classified as ‘methylated’ by a ratio of cytosine/thymine peak A > 3.0, B > 3.0 and C > 1.0.

Additional file 4: Supplementary Fig. S4. Effect of the number of methylated CpG sites on the hazard of post-recurrence mortality: the patients’ methylated CpG sites were plotted against the patients’ martingale residuals of the model without the variable “methylated CpG sites.” The red line shows the corresponding LOWESS (locally weighted scatterplot smoothing) curve and gives a hint for the true effect of the number of ‘methylated’ CpG sites on the hazard of mortality for glioblastoma patients with post-recurrence treatment A) with (n = 88) and B) without (n = 120) TMZ re-exposition.

Additional file 5: Supplementary Table S1. Survival data in different subgroups.

Additional file 6: Supplementary Table S2. Study population.

Abbreviations
18F-FET PET: 18F-(2-[18F]fluoroethyl)-1-tyrosine positron emission tomography; bp: Base pair; CI: Confidence interval; CpG: Cytosine-Guanine dinucleotide; CRAN: Comprehensive R Archive Network; C/T: Cytosine/thymine; DMR-2: Differentially methylated region-2; DNA: Deoxyribonucleic acid; GTR: Gross-total tumor resection; IDH1/2: Isocitrate dehydrogenase 1/2; IRB: Institutional Review Board; KPS: Karnofsky performance status; LOWESS: Locally weighted scatterplot smoothing; MGMT: O-6-Methylguanine-DNA methyltransferase; MRI: Magnetic resonance imaging; MSP: Methyl-specific polymerase-chain-reaction; NGS: Next-generation-sequencing; PFS: Progression-free survival; PRS: Post-recurrence survival; RANO: Response assessment in neuro-oncology; RT: Radiotherapy; OS: Overall survival; OTR: Open tumor resection; STR: Subtotal tumor resection; Seeq: Sanger sequencing; TMZ: Temozolomide; WHO: World Health Organization.

Acknowledgements
We want to give special thanks to Mrs. Janina Mielke, Mr. Michael Ruiter and Mr. Peer Schmitz of the Center for Neuropathology and Prion Research, University Hospital of Munich (LMU), Germany, for providing technical support for data acquisition. Moreover, the generous financial support of Dr. Dirk Ippen and Mrs. Marlene Ippen for bearing the publication charges is thankfully acknowledged.

Authors’ contributions
SS, ML, SE, AG, JCT: Conception and design of the work. SS, MN, SE, AG: Data acquisition. SS, ML: Data analysis. SS, PK, JCT: Drafting the manuscript. All authors: Revising the manuscript critically for important intellectual content. All authors have seen and approved submission of the manuscript. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. The study was not financially or materially supported by or any income was received from a commercial sponsor or the NIH, Welcome Trust, HHMI or other foundations requiring open access.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was reviewed and approved by the local Institutional Review Board (IRB) of the Ludwig-Maximilian-University Munich (approval number 703/16), and a waiver of consent was issued by the IRB.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Neurosurgery, University Hospital, LMU Munich, Maximiliansstrasse 15, 81377 Munich, Germany. 2 German Cancer Consortium (DKTK), Partner Site Munich, Pettenkoferstrasse 8a, 80336 Munich, Germany. 3 Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Maximiliansstrasse 15, 81377 Munich, Germany. 4 Department of Radiation Oncology, University Hospital, LMU Munich, Maximiliansstrasse
4. Bonello N, Sampson J, Burn J, Wilson IJ, McGrown G, Margison GP, Bady P, Sciuscio D, Diserens A-C, Bloch J, van den Bent MJ, Marosi C, 1. Binder H, Schumacher M (2008) Allowing for mandatory covariates in Bayesian inference supports a location and neighbour-dependent model of DNA methylation propagation at the MGMT gene promoter in lung tumours. J Theor Biol 336:87–95. https://doi.org/10.1016/j.jtbi.2013.07.019
5. Bonello N, Sampson J, Burn J, Wilson I, McGrown G, Margison GP, Thornicroft M, Crossbie P, Povey AC, Sztabinez-Korel M, Walters K (2013) Bayesian inference supports a location and neighbour-dependent model of DNA methylation propagation at the MGMT gene promoter in lung tumours. Br J Cancer 101(1):124–131. https://doi.org/10.1038/bjc.2014.65
6. Everhard S, Trablod R, Brucker D, Erös C, Egensperger R, La Fougere C, Gebel W, Rühm A, Kretzschmar HA, Tonn JC, Hemms J, Giese A, Kreth FW (2014) Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir (Wien) 156(8):1427–1440. https://doi.org/10.1007/s00701-014-2073-1
7. Esteller M, García-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vaneclotchka N, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350–1354. https://doi.org/10.1056/NEJM200011203431901
8. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59(4):793–797
9. Everhard S, Tost J, EI Abdalaoui H, Crinière E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, LaFougere C, Gebel W, Rühm A, Kretzschmar HA, Tonn JC, Hemms J, Giese A, Kreth FW (2014) Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir (Wien) 156(8):1427–1440. https://doi.org/10.1007/s00701-014-2073-1
10. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann R-D, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovaniz M, Bullinger L, GaliLdikis N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schöfer N et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393(10172):678–688. https://doi.org/10.1016/S0140-6736(18)31791-4
11. Hegi ME, Genbrugge L, Batory P, Hauri H, Hainfellner JA, Jülicher B, Hau P, Kortmann R-D, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovaniz M, Bullinger L, Gallickis N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schöfer N et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393(10172):678–688. https://doi.org/10.1016/S0140-6736(18)31791-4
12. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of MGMT promoter hypermethylation as demonstrated in serial stereotactic biopsies in glioblastoma patients. Acta Neuropathol Commun 7(1):89. https://doi.org/10.1186/2045-7066-7-89
13. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann R-D, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovaniz M, Bullinger L, GaliLdikis N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schöfer N et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393(10172):678–688. https://doi.org/10.1016/S0140-6736(18)31791-4
27. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

28. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330

29. Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Statistics for biology and health. Springer, New York

30. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermann F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJ, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wink W (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18(6):e315–e329. https://doi.org/10.1016/S1470-2045(17)30194-8

31. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Diegoot J, Wick W, Gilbert MR, Lassman AB, Tsen C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. https://doi.org/10.1200/JCO.2009.26.3541

32. Wen PY, Weller M, Lee EQ, Alexander BA, Bamholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Louth E, Lim M, Mehta MP, Mellinghoff IK, Minniti Q, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC et al (2020) Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus review on current management and future directions. Neuro Oncol. https://doi.org/10.1093/neuonc/noaa106

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.